Zabopegdutide (DD01)_Dosage, benefits & legal status
Also known as DD01
Nearly the same peptide as efinopegdutide, carried on a large PEG instead of an antibody fragment. In a 67-person phase 2, 76% on the drug cut liver fat by at least 30% in 12 weeks, against 12% on placebo.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Zabopegdutide (DD01)?
Plain language first. The technical label stays, but it never stands alone.Overview
Fat building up in the liver, and the inflammation it can bring (MASH), can scar the liver over time. In a 67-person phase 2, 76% of people on weekly zabopegdutide cut their liver fat by at least 30% in 12 weeks, against 12% on placebo. At 48 weeks, MASH cleared on biopsy in 62.5% against 5.3%, but these are company topline figures from only 35 people and are not yet peer reviewed.
Zabopegdutide is a 30-residue glucagon-based peptide with Aib at position 2, a glutamate 16 to lysine 20 lactam bridge and an added C-terminal cysteine amide carrying a large branched PEG; GSRS puts the conjugate at about 57 kDa against about 3.8 kDa for the peptide, so it is mostly PEG by mass. It activates GLP-1 and glucagon receptors, about 11 times more strongly at GLP-1 by the company's figures. The peptide matches efinopegdutide's except at positions 17 and 18, but it has no antibody Fc part; D&D Pharmatech develops it through its subsidiary Neuraly.
What it's used for
An experimental weekly injection for fatty liver disease (MASLD and its inflamed form, MASH) in adults with overweight or obesity. It is not approved anywhere.
How does Zabopegdutide (DD01) work?
What it does in the body, and where.Zabopegdutide switches on two hormone receptors, mostly GLP-1 with some glucagon, from a peptide held in the body by a large PEG.
- 01The GLP-1 sideGLP-1 receptor activity lowers appetite, slows stomach emptying and improves insulin release when blood sugar is high. By the company's figures it is about 11 times more potent at GLP-1 receptors than at glucagon receptors.
- 02The glucagon sideGlucagon receptors on the liver raise fat burning and lower stored fat. The company links this to liver fat falling 37.4% in phase 2 patients who lost under 5% of their weight.
- 03The PEGThe large branched PEG slows absorption and clearance: levels peak about 6 days after a dose and the half-life is about 7 to 8 days, allowing weekly injection. Aib at position 2 resists the enzyme DPP-4, and a lactam ring holds the peptide's helix in shape.
Hits 2 receptors at once.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
Liver fat at 12 weeks (phase 2)
Investigational- Human trial67 adults with overweight or obesity and MASLD or MASH: 76% (25 of 33) against 12% (4 of 34) cut liver fat by at least 30% on MRI (adjusted relative risk 6.3, P<0.0001).
- Human trialSide effects in 85% against 68% on placebo, most often nausea, diarrhea and vomiting.
Deeper liver fat responses and weight
Investigational- Human trial72.7% against 5.9% cut liver fat by more than half, and 48.5% against 0% reached normal liver fat (under 5%); the placebo figures come from the company's June 2025 release.
- Human trialWeight fell 3.8% by week 12 and 6.4% by week 24 on the drug; in those who lost under 5% of their weight, liver fat still fell 37.4%.
Liver biopsy at 48 weeks
Investigational- Human trialMASH resolved without worsening fibrosis in 62.5% against 5.3% (p=0.0003); fibrosis improved by at least one stage in 50.0% against 15.8% (p=0.0323); both in 37.5% against 5.3%.
- No dataCompany topline from a per-protocol group of 35 (16 of 33 on the drug, 19 of 34 on placebo), about half of those enrolled, not yet peer reviewed.
Phase 1
Investigational- human-early4 weeks of weekly doses in adults with obesity, type 2 diabetes and fatty liver: the company reported a mean liver fat fall of more than 50% at the two highest doses against under 5% on placebo, with falls even at doses that caused no significant weight loss.
It is often called simply an investigational peptide, but it is a 30-residue peptide joined to a large branched PEG: GSRS puts the whole molecule at about 57 kDa against about 3.8 kDa for the peptide, and the company has not stated the PEG's size. It is also reported as too small and short to show longer-term results, but the trial ran 48 weeks and the company released biopsy results in May 2026; those come from a per-protocol group of 35 and are not peer reviewed. A '37.0%' fall in liver fat at 12 weeks has been reported for the whole group, but the company's 37.4% applies only to people who lost under 5% of their weight; the group average was 62.3% against 8.3%. Stopping for side effects is reported as 4 in total with 3 on the drug, while the abstract summary gives 4 on the drug against 1 on placebo. The phase 1 is given as 107 people by the company and 255 in its registry. The human half-life is 7 to 8 days; 11 days came from monkeys. Early materials called it 'imbalanced' and later ones 'balanced', but the company's 11:1 GLP-1 to glucagon ratio makes it GLP-1-weighted. It is not efinopegdutide: the peptides differ at positions 17 and 18, and efinopegdutide's PEG ends on an antibody Fc part.
The published record
Papers and trials about Zabopegdutide (DD01)
4 papers tagged human · 1 not reviews or lab · 1 clinical trial publications
2 registered trials · none with posted results
Furthest stage reached: Phase 2, completed, no results posted
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about Zabopegdutide (DD01)
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
About 7 to 8 days
How much, and do you cycle it?
The range, and whether you take breaks.20 mg weekly for 2 weeks, then 40 mg weekly (phase 2 trial), weekly. Continuous in the trials Trial dose
Given every week for 48 weeks after a two-week lower starting dose, with no planned breaks.
How long does it stay in the body?
The half-life, and where the figure comes from.About 7 to 8 daysTrial protocol
Measured in adults with overweight or obesity, type 2 diabetes and fatty liver; levels peak about 6 days after a dose. From company releases, not a published pharmacokinetic paper. The 11-day figure sometimes quoted came from monkeys.
Source: D&D Pharmatech releases, May 2, 2023 and June 16, 2025
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized Zabopegdutide (DD01) keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.Solubility, computed: 27% charged residues, 37% hydrophobic. Water usually sufficient.
A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.
Who should avoid it
- Not studied in liver cirrhosis (fibrosis stage F4) or after any liver decompensation
- Not studied in people with past or current pancreatitis, or a personal or family history of medullary thyroid cancer
- Not studied in type 1 diabetes, or in type 2 diabetes treated with insulin or GLP-1 drugs
- Not studied in pregnancy or breastfeeding
- Not studied in people with other active or chronic liver disease, or a history of alcohol or drug abuse
Stop and get help
- Severe or lasting pain in the upper abdomen: the phase 2 had one serious case of abdominal pain and one of acute gallbladder inflammation
- Vomiting or diarrhea that stops you keeping fluids down
Common effects
- Any side effect in 85% (28 of 33) against 68% (23 of 34) on placebo over 12 weeks
- Nausea, diarrhea and vomiting were the most common; rates for each have not been published
- 4 people stopped for side effects against 1 on placebo; the company said 3 stopped for gut effects
- Two serious events (abdominal pain, acute cholecystitis) against none on placebo, and no deaths
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Zabopegdutide (DD01) approved?
And where the numbers on this page come from.No. Zabopegdutide (DD01) is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- Checked16 October 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesFDA GSRS substance record, zabopegdutide (UNII 3Y9RY78VKT)FDA GSRS names entry, zabopegdutideNoureddin M et al., Lancet Gastroenterology & Hepatology 2026;11:887-896ClinicalTrials.gov, NCT06410924DocWire News, summary of the Lancet abstract (2026)EMJ Reviews, DD01 reduced liver fat in MASH (2026)D&D Pharmatech, phase 2 topline (June 16, 2025)D&D Pharmatech, 48-week histology results (May 27, 2026)D&D Pharmatech, Lancet publication release (July 21, 2026)D&D Pharmatech, phase 1 results (May 2, 2023)D&D Pharmatech, phase 1 start (March 30, 2021)Daily Pharm, DD01 48-week results (2026)ClinicalTrials.gov, NCT04812262
What has happened recently
Not approved anywhere. D&D Pharmatech, based in South Korea and Gaithersburg, Maryland, develops it through its subsidiary Neuraly, Inc. A phase 1 (NCT04812262) ran from February 24, 2021 to February 14, 2023. The phase 2 DD01-DN-02 (NCT06410924) started on June 13, 2024 and was completed on April 21, 2026; 12-week results were announced on June 16, 2025 and published in Lancet Gastroenterology & Hepatology on July 21, 2026, and 48-week biopsy results were released at the EASL congress on May 27, 2026. D&D's June 16, 2025 release states that the FDA has granted Fast Track designation for MASH. The name zabopegdutide was proposed on the WHO's INN list 134 (WHO Drug Information, 2025 volume, posted in January 2026). As of late May 2026 no licensing deal had been reported, and no phase 3 has been announced.
You can compare this against the whole library, or read how to check a seller.
What else is like Zabopegdutide (DD01)?
Others in GLP-1 agonists, side by side.If you're weighing Zabopegdutide (DD01), it's worth reading Zovaglutide (ZT-002), Retatrutide, and Tirzepatide in the same class.
Nearly the same peptide as efinopegdutide, carried on a large PEG instead of an antibody fragment. In a 67-person phase 2, 76% on the drug cut liver fat by at least 30% in 12 weeks, against 12% on placebo.
- Dose
- 20 mg weekly for 2 weeks, then 40 mg weekly (phase 2 trial)
- How often
- Weekly
An experimental once-a-month weight-loss shot.
- Dose
- 80 up to 160 mg per month (trial doses)
- How often
- Monthly
An experimental weekly shot with some of the biggest weight-loss numbers yet in trials.
- Dose
- 1 up to 12 mg per dose (start low, increase slowly)
- How often
- Weekly
The drug in Mounjaro and Zepbound: a weekly shot for major weight loss and blood sugar.
- Dose
- 2.5 up to 15 mg per week (start low, increase slowly)
- How often
- Weekly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- FDA GSRS substance record, zabopegdutide (UNII 3Y9RY78VKT)(2026)30-residue sequence with Aib at 2, a glutamate 16 to lysine 20 lactam and a PEG on cysteine 30; average MW 57,008 Da; CAS 2468152-46-5; GLP-1 and glucagon receptor agonist.
- FDA GSRS names entry, zabopegdutide(2026)Branched, methoxy-capped PEG joined to the C-terminal cysteine amide through a thiosuccinimide linker; PEG size not stated.
- Noureddin M et al., Lancet Gastroenterology & Hepatology 2026;11:887-896(2026)DD01-DN-02 12-week results: at least a 30% relative fall in liver fat in 76% against 12% on placebo.
- ClinicalTrials.gov, NCT06410924(2026)Randomized, double-blind, 48 weeks; 67 enrolled; completed April 21, 2026; sponsor Neuraly; adults 18 to 70; cirrhosis, pancreatitis and medullary thyroid cancer history excluded.
- DocWire News, summary of the Lancet abstract (2026)(2026)25 of 33 against 4 of 34; adjusted odds ratio 28.8 and relative risk 6.3; side effects 85% against 68%; 4 against 1 stopped for side effects.
- EMJ Reviews, DD01 reduced liver fat in MASH (2026)(2026)12 US sites; 78% with biopsy-confirmed MASH; serious events in 2 against 0.
- D&D Pharmatech, phase 2 topline (June 16, 2025)(2025)Mean liver fat fall 62.3% against 8.3%; 11:1 GLP-1 to glucagon potency; half-life 7 to 8 days with a peak at about 6 days; FDA Fast Track.
- D&D Pharmatech, 48-week histology results (May 27, 2026)(2026)Per-protocol group of 35: MASH resolution 62.5% against 5.3%; fibrosis improvement 50.0% against 15.8%.
- D&D Pharmatech, Lancet publication release (July 21, 2026)(2026)72.7% cut liver fat by more than half and 48.5% reached normal liver fat; weight down 3.8% at 12 weeks and 6.4% at 24; 37.4% liver fat fall with under 5% weight loss.
- D&D Pharmatech, phase 1 results (May 2, 2023)(2023)Weekly doses up to 80 mg for 4 weeks; mean liver fat fall over 50% at the two highest doses against under 5% on placebo; human half-life 7 to 8 days; 107 enrolled.
- D&D Pharmatech, phase 1 start (March 30, 2021)(2021)Neuraly is a D&D subsidiary; 11-day half-life in non-human primates.
- Daily Pharm, DD01 48-week results (2026)(2026)Confirms DD01 is zabopegdutide; no licensing deal as of May 2026.
- ClinicalTrials.gov, NCT04812262(2023)Phase 1 single and multiple ascending doses, February 24, 2021 to February 14, 2023; 255 enrolled per the registry.
Beyond these, 5 records are indexed. Browse the records